The findings from our study highlight the potential of GPR35 agonists to provide non–opioid-based analgesia in GI diseases, such as IBS and IBD, because of their ability to prevent neurogenic colonic afferent activation, mechanosensitisation, and colonic contractility through the inhibition of SP release. The gene discussed is GPR35; the disease is irritable bowel syndrome.